Fertility, gonadal and sexual function in survivors of testicular cancer

British Journal of Cancer

Volumn 93, Issue 2, 2005, Pages 200-207

  Huddart, R A ^a   Norman, A ^b   Moynihan, C ^a   Horwich, A ^a   Parker, C ^a   Nicholls, E ^a   Dearnaley, D P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Fertility; Hormones; Quality of life; Testicular cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; FOLLITROPIN BLOOD LEVEL; GONAD DYSFUNCTION; GONAD FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE FERTILITY; ORCHIECTOMY; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEMINOMA; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SOCIAL STATUS; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HUMANS; INFERTILITY, MALE; MALE; MIDDLE AGED; ORCHIECTOMY; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SURVIVORS; TESTICULAR DISEASES; TESTICULAR NEOPLASMS;

EID: 23644445943     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602677     Document Type: Article

References (31)

1. Aass N, Fossa SD, Theodorsen L, Norman N (1991) Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 27: 1087-1091
2. Bates AS, Van't Hoff W, Jones PJ, Clayton RN (1996) The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 81: 1169-1172
3. Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ (1996) Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 73: 1108-1114
4. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923-2932
5. Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jager N, Klingmuller D (1997) Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 158: 844-850
6. Brennemann W, Stoffel-Wagner B, Wichers M, Helmers A, Albers P, Mezger J, Klingmuller D (1998) Pretreatment follicle-stimulating hormone: a prognostic serum marker of spermatogenesis status in patients treated for germ cell cancer. J Urol 159: 1942-1946
7. Drasga RE, Einhorn LH, Williams SD, Patel DN, Stevens EE (1983) Fertility after chemotherapy for testicular cancer. J Clin Oncol 1: 179-183
8. Fayers P, Aaronson N, Bjordal K, Groenvold M, VCurran D, Bottomley A, Group, o.b.o.t.E.Q.o.L (2001) The EORTC QLQ-C30 Scoring Manual EORTC Quality of Life Group, Brussels. European Organisation for Research and Treatment of Cancer, Brussels
9. Fossa SD, Aabyholm T, Vespestad S, Norman N, Ous S (1993) Semen quality after treatment for testicular cancer. Eur Urol 23: 172-176
10. Fossa SD, Kravdal O (2000) Fertility in Norwegian testicular cancer patients. Br J Cancer 82: 737-741
11. Fosså SD, Ous S, Abyholm T, Loeb M (1985) (I) Post-treatment fertility in patients with testicular cancer. I. Influence of retroperitoneal lymph node dissection on ejaculatory potency. Br J Urol 57: 204-209
12. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8: 41-47
13. Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W (2001) The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 91: 1297-1303
14. Hansen SW, Berthelsen JG, von der Maase H (1990) Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin vs surveillance. J Clin Oncol 8: 1695-1698
15. Howell SJ, Radford JA, Smets EM, Shalet SM (2000) Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction. Br J Cancer 82: 789-793
16. Huddart R, Norman A, Shahidi M, Horwich A, Coward D, Nicholls E, Dearnley D (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21: 1513-1523
17. Huddart RA, Norman A (2003) Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy. Br J Cancer 89: 1143-1144; author reply 1145
18. Jacobsen KD, Theodorsen L, Fossa SD (2001) Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. J Urol 165: 93-96
19. Kreuser ED, Kurrle E, Hetzel WD, Heymer B, Porzsolt F, Hautmann R, Gaus W, Schlipf U, Pfeiffer EF, Heimpel H (1989) Reversible germ cell toxicity following aggressive chemotherapy in patients with testicular tumors: results of a prospective study. Klin Wochenschr 67: 367-378
20. Lampe H, Dearnaley DP, Price A, Mehta J, Powles R, Nicholls J, Horwich A (1995) High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours. Eur J Cancer 5: 717-723
21. Leitner SP, Bosl GJ, Bajorunas D (1986) Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol 4(10): 1500-1505
22. Moller H, Skakkebaek N (1999) Risk of testicular cancer in subfertile men: case-control study. BMJ 318: 559-562
23. Nord C, Bjoro T, Ellingsen D, Mykletun A, Dahl O, Klepp O, Bremnes RM, Wist E, Fossa SD (2003) Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 44: 322-328
24. Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkeaek NE, Hansen SW, von der Maase H (2002) Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 20: 1537-1543
25. Petersen PM, Hansen SW, Giwercman A, Rorth M, Skakkebaek NE (1994) Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 5: 355-358
26. Petersen PM, Skakkebaek NE, Vistisen K, Rorth M, Giwercman A (1999) Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 17: 941-947
27. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E (1997) Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab 82: 682-685
28. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86: 4261-4267
29. Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, Reiners C, Mockel C, Seeber S, Scheulen ME (2002) Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for nonseminomatous testicular cancer. Ann Oncol 13(2): 229-236
30. Stuart NS, Woodroffe CM, Grundy R, Cullen MH (1990) Long-term toxicity of chemotherapy for testicular cancer - the cost of cure. Br J Cancer 61: 479-484
31. United Kingdom Testicular Cancer Study Group (1994) Aetiology of testicular cancer; association with congenital abnormalities, age at puberty, infertility, and exercise. BMJ 308: 1393-1399